Search research articles
Contact Us
Filters
Showing results (51-60 of 118) with videos related to
Page
of 12
Sort By:
The Journal of Emergency Medicine
|
January 1, 1990
Deep venous thrombosis of the upper extremity: diagnosis and treatment
E B Bolgiano, M M Foxwell, B J Browne, et al.
Journal of Palliative Medicine
|
July 8, 2024
Everyday Ethics or Deference to Expertise: Experiences of Pediatric Palliative Care Teams with Ethics Consultancy
Anessa M Foxwell, Connie M Ulrich, Jennifer K Walter, et al.
Journal of Palliative Medicine
|
May 25, 2017
Palliative Care Office Hours for Patients with Hematologic Malignancies: An Innovative Model for Symptom Management and Education
Anessa M Foxwell, Mary E Moyer, David J Casarett, et al.
Expert Reviews in Molecular Medicine
|
August 25, 2005
Molecular therapeutic targets in rheumatoid arthritis
Sandra M Sacre, Evangelos Andreakos, Peter Taylor, et al.
Annals of the Rheumatic Diseases
|
March 14, 2002
High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach
B M Foxwell, S Yoshimura, J Bondeson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 15, 2006
Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant
E Andreakos, R O Williams, J Wales, et al.
Transplantation Proceedings
|
April 1, 1988
Biologic significance of cyclosporine metabolites
B Ryffel, B M Foxwell, M J Mihatsch, et al.
Toxicology
|
January 1, 1985
The use of anti-ricin antibodies to protect mice intoxicated with ricin
B M Foxwell, S I Detre, T A Donovan, et al.
Biochemical Pharmacology
|
March 3, 1992
Covalent binding of cyclosporine inhibits irreversibly T-lymphocyte activation
B Ryffel, G Woerly, V F Quesniaux, et al.
Annals of the Rheumatic Diseases
|
December 1, 1999
The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?
M Feldmann, J Bondeson, F M Brennan, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 118) with videos related to
Sort By:
Page
of 12
The Journal of Emergency Medicine
|
January 1, 1990
Deep venous thrombosis of the upper extremity: diagnosis and treatment
E B Bolgiano, M M Foxwell, B J Browne, et al.
Journal of Palliative Medicine
|
July 8, 2024
Everyday Ethics or Deference to Expertise: Experiences of Pediatric Palliative Care Teams with Ethics Consultancy
Anessa M Foxwell, Connie M Ulrich, Jennifer K Walter, et al.
Journal of Palliative Medicine
|
May 25, 2017
Palliative Care Office Hours for Patients with Hematologic Malignancies: An Innovative Model for Symptom Management and Education
Anessa M Foxwell, Mary E Moyer, David J Casarett, et al.
Expert Reviews in Molecular Medicine
|
August 25, 2005
Molecular therapeutic targets in rheumatoid arthritis
Sandra M Sacre, Evangelos Andreakos, Peter Taylor, et al.
Annals of the Rheumatic Diseases
|
March 14, 2002
High efficiency gene transfer is an efficient way of defining therapeutic targets: a functional genomics approach
B M Foxwell, S Yoshimura, J Bondeson, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
September 15, 2006
Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant
E Andreakos, R O Williams, J Wales, et al.
Transplantation Proceedings
|
April 1, 1988
Biologic significance of cyclosporine metabolites
B Ryffel, B M Foxwell, M J Mihatsch, et al.
Toxicology
|
January 1, 1985
The use of anti-ricin antibodies to protect mice intoxicated with ricin
B M Foxwell, S I Detre, T A Donovan, et al.
Biochemical Pharmacology
|
March 3, 1992
Covalent binding of cyclosporine inhibits irreversibly T-lymphocyte activation
B Ryffel, G Woerly, V F Quesniaux, et al.
Annals of the Rheumatic Diseases
|
December 1, 1999
The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards?
M Feldmann, J Bondeson, F M Brennan, et al.
Page
of 12